Quick Answer
Traws Pharma, Inc. reported Total Assets of $24.96 million for the year ending 2024.
- Traws Pharma, Inc. showed an increase of +10.0% in Total Assets from 2023 to 2024.
- This data is from Traws Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2012 to 2024 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2013: $57.91 million | Q3 2013: $122.72 million | Q1 2014: $89.72 million | Q2 2014: $74.57 million | Q3 2014: $62.27 million | Q1 2015: $36.71 million | Q2 2015: $27.74 million | Q3 2015: $25.97 million | Q1 2016: $19.64 million | Q2 2016: $16.20 million | Q3 2016: $28.09 million | Q1 2017: $16.55 million | Q2 2017: $16.10 million | Q3 2017: $8.80 million | Q1 2018: $8.62 million | Q2 2018: $30.20 million | Q3 2018: $23.14 million | Q1 2019: $11.34 million | Q2 2019: $8.58 million | Q3 2019: $6.01 million | Q1 2020: $32.07 million | Q2 2020: $28.20 million | Q3 2020: $25.21 million | Q1 2021: $48.85 million | Q2 2021: $44.38 million | Q3 2021: $59.99 million | Q1 2022: $51.42 million | Q2 2022: $48.07 million | Q3 2022: $43.78 million | Q1 2023: $35.06 million | Q2 2023: $30.47 million | Q3 2023: $27.04 million | Q1 2024: $18.17 million | Q2 2024: $18.69 million | Q3 2024: $8.94 million | Q4 2024: $24.96 million | Q1 2025: $19.06 million | Q2 2025: $15.62 million | Q3 2025: $12.44 million.
- Over the full 13 years of available data (2012 to 2024), Traws Pharma, Inc.'s Total Assets has declined by 70.2%.
- Historical annual values: Fiscal year 2024: $24.96 million | Fiscal year 2023: $22.68 million | Fiscal year 2022: $39.37 million | Fiscal year 2021: $55.48 million | Fiscal year 2020: $19.99 million | Fiscal year 2019: $23.67 million | Fiscal year 2018: $17.92 million | Fiscal year 2017: $4.98 million | Fiscal year 2016: $23.23 million | Fiscal year 2015: $23.45 million | Fiscal year 2014: $47.34 million | Fiscal year 2013: $105.15 million | Fiscal year 2012: $83.85 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: